Who Owns United Therapeutics CORP (UTHR)? 13F Institutional Holders (Q2 2026)

UTHR ranks #574 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

UTHR is a top-conviction position for Avoro Capital Advisors LLC — at 13.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in UTHR belongs to BlackRock, Inc., but the position matters far more to Avoro Capital Advisors LLC, who has 13.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Israel Englander has added to its UTHR position for two straight quarters, increasing it by $231.6M to reach $262.8M today.

Cliff Asness has trimmed its UTHR position for two straight quarters, cutting it by $329.9M while still holding $294.6M.

UTHR is down 4% today, but institutions show net buying of $10.1B this quarter — a divergence between today's price move and the underlying institutional flow.

UTHR posted net income of $1.3B over the trailing twelve months, and currently trades at a P/E of 18.0.

• Profitable — net income of $1.3B over the trailing twelve months
• Revenue grew 2.5% year over year
• Net income improved year over year, from $1.2B to $1.3B
• Generated $1.6B in positive operating cash flow
• Current ratio of 6.60x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range